<DOC>
	<DOCNO>NCT00005056</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness bryostatin 1 treat patient progressive kidney cancer</brief_summary>
	<brief_title>Bryostatin 1 In Treating Patients With Progressive Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient progressive hypernephroma treat bryostatin 1 . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive bryostatin 1 IV 24 hour day 1 , 8 , 15 . Treatment repeat every 4 week 2 course . For patient stable respond disease completion course 2 , treatment repeat every 4 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 14-25 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive hypernephroma Bidimensionally measurable disease document progression within 2 month prior study entry Sites measurable evaluable disease must outside prior radiation port No active symptomatic CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Greater 3 month Hematopoietic : Granulocyte count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 1.17 mg/dL SGOT SGPT less 2.5 time normal Renal : Creatinine le 1.70 mg/dL Other : No prior concurrent malignancy except adequately treat cone biopsied carcinoma situ cervix basal cell squamous cell skin cancer No severe uncontrolled nonmalignant systemic disease would make patient poor medical risk No uncontrolled active infection Not pregnant nursing Fertile patient must use effective contraception 4 week study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : No prior chemotherapy Endocrine therapy : At least 4 week since prior endocrine therapy steroid recover No concurrent systemic steroid Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>